Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia

References

• InokuchiKChronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapiesJ Nihon Med Sch2006734178192
   Google Scholar
• ChandraHSHeistekampNCHungerfordAPhiladelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosomeCancer Genet2011204417117921536234
   PubMed Web of Science ®Google Scholar
• ChenYPengCLiDLiSMolecular and cellular bases of chronic myeloid leukemiaProtein Cell20101212413221203982
   PubMed Web of Science ®Google Scholar
• GroffenJStephensonJRHeisterkampNde KleinABartramCRGrosveldGPhiladelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22Cell198436193996319012
   PubMed Web of Science ®Google Scholar
• ShtivelmanELifshitzBGaleRPCanaaniEFused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature198531560205505542989692
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaACortesJMolecular biology of bcr-abl1-positive chronic myeloid leukemiaBlood200911381619163018827185
   PubMed Web of Science ®Google Scholar
• DeiningerMVGoldmanJMMeloJVThe molecular biology of chronic myeloid leukemiaBlood200096103343335611071626
   PubMed Web of Science ®Google Scholar
• KantarjianHMGilesFQuintás-CardamaACortesJImportant therapeutic targets in chronic myelogenous leukemiaClin Cancer Res20071341089109717317816
   PubMed Web of Science ®Google Scholar
• RenRMechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemiaNat Rev Cancer20055317218315719031
   PubMed Web of Science ®Google Scholar
• PendergastAMQuilliamLACripeLDBCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor proteinCell19937511751858402896
   PubMed Web of Science ®Google Scholar
• IlariaRLJrVan EttenRAP210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family membersJ Biol Chem19962714931704317108940193
   PubMed Web of Science ®Google Scholar
• ChaiSKNicholsGLRothmanPConstitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patientsJ Immunol199715910472047289366395
   PubMed Web of Science ®Google Scholar
• SillaberCGesbertFFrankDASattlerMGriffinJDSTAT5 activation contributes to growth and viability in Bcr/Abl-transformed cellsBlood20009562118212510706883
   PubMed Web of Science ®Google Scholar
• SkorskiTKanakarajPNieborowska-SkorskaMPhosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cellsBlood19958627267367606002
   PubMed Web of Science ®Google Scholar
• NaughtonRQuineyCTurnerSDCotterTGBcr-Abl-mediated redox regulation of the PI3K/AKT pathwayLeukemia20092381432144019295548
   PubMed Web of Science ®Google Scholar
• SattlerMSalgiaROkudaKThe proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathwayOncogene19961248398468632906
   PubMed Web of Science ®Google Scholar
• FrankeTFKaplanDRCantleyLCPI3K: downstream AKTion blocks apoptosisCell19978844354379038334
   PubMed Web of Science ®Google Scholar
• ZouXRudchenkoSWongKCalameKInduction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinasesGenes Dev19971156546629119229
   PubMed Web of Science ®Google Scholar
• LiFSethiGTargeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapyBiochim Biophys Acta20101805216718020079806
   PubMed Web of Science ®Google Scholar
• JaganiZSinghAKhosravi-FarRFoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosisBiochim Biophys Acta200817851638417980712
   PubMed Web of Science ®Google Scholar
• NevianiPSanthanamRTrottaRThe tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET proteinCancer Cell20058535536816286244
   PubMed Web of Science ®Google Scholar
• SchifferCABCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemiaN Engl J Med2007357325826517634461
   PubMed Web of Science ®Google Scholar
• TorgersonSRHaddadRYAtallahEChronic myelogenous leukemia for primary care physiciansDis Mon201258416817622449366
   PubMed Web of Science ®Google Scholar
• VardimanJHarrisNLBrunningRDThe World Health Organization (WHO) classification of the myeloid neoplasmsBlood200210072292230212239137
   PubMed Web of Science ®Google Scholar
• HehlmannRHeimpelHHasfordJRandomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study GroupBlood19948412406440777994025
   PubMed Web of Science ®Google Scholar
• TalpazMKantarjianHKurzrockRTrujilloJMGuttermanJUInterferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patientsAnn Intern Med199111475325382001086
   PubMed Web of Science ®Google Scholar
• HenkesMvan der KuipHAulitzkyWETherapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark)Ther Clin Risk Manag20084116318718728706
   PubMedGoogle Scholar
• GuglielmiCArceseWDazziFDonor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell doseBlood2002100239740512091328
   PubMed Web of Science ®Google Scholar
• LugoTGPendergastAMMullerAJWitteONTyrosine kinase activity and transformation potency of bcr-abl oncogene productsScience19902474946107910822408149
   PubMed Web of Science ®Google Scholar
• ZimmermannJCaravattiGMettHPhenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)Arch Pharm (Weinheim)199632973713768764886
   PubMed Web of Science ®Google Scholar
• ZimmermannJBuchdungerEMettHMeyerTLydonNBPotent and selective inhibitors of the Abl kinase: phenylamino-pyrimidine (PAP) derivativesBioorg Med Chem Lett19977187192
   Web of Science ®Google Scholar
• SavageDGAntmanKHImatinib mesylate – a new oral targeted therapyN Engl J Med2002346968369311870247
   PubMed Web of Science ®Google Scholar
• SchindlerTBornmannWPellicenaPMillerWTClarksonBKuriyanJStructural mechanism for STI-571 inhibition of abelson tyrosine kinaseScience200028954861938194210988075
   PubMed Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsNat Med1996255615668616716
   PubMed Web of Science ®Google Scholar
• BuchdungerEZimmermannJMettHSelective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine classProc Natl Acad Sci U S A1995927255825627708684
   PubMed Web of Science ®Google Scholar
• BuchdungerEZimmermannJMettHInhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivativeCancer Res19965611001048548747
   PubMed Web of Science ®Google Scholar
• BeranMCaoXEstrovZSelective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)Clin Cancer Res199847166116729676840
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCle CoutrePMologniLInhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosisBlood Cells Mol Dis19972333803949446752
   PubMed Web of Science ®Google Scholar
• DeiningerMWGoldmanJMLydonNMeloJVThe tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cellsBlood1997909369136989345054
   PubMed Web of Science ®Google Scholar
• DanSNaitoMTsuruoTSelective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR – ABL tyrosine kinase, CGP 57148Cell Death Differ19985871071510200527
   PubMed Web of Science ®Google Scholar
• HoltzMSSlovakMLZhangFSawyersCLFormanSJBhatiaRImatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferationBlood200299103792380011986238
   PubMed Web of Science ®Google Scholar
• AppelSBoehmlerAMGrünebachFImatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cellsBlood2004103253854414504105
   PubMed Web of Science ®Google Scholar
• DaleyGQVan EttenRABaltimoreDInduction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosomeScience199024749448248302406902
   PubMed Web of Science ®Google Scholar
• ZhangXRenRBcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemiaBlood19989210382938409808576
   PubMed Web of Science ®Google Scholar
• WolffNCIlariaRLJrEstablishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571Blood20019892808281611675355
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med2001344141031103711287972
   PubMed Web of Science ®Google Scholar
• DrukerBJSawyersCLKantarjianHActivity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosomeN Engl J Med2001344141038104211287973
   PubMed Web of Science ®Google Scholar
• SawyersCLHocchausAFeldmanEImatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood200299103530353911986204
   PubMed Web of Science ®Google Scholar
• KantarjianHMVellekoopLMcCredieKBIntensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemiaJ Clin Oncol1985321922003855444
   PubMed Web of Science ®Google Scholar
• KantarjianHMKeatingMJTalpazMChronic myelogenous leukemia in blast crisis. Analysis of 242 patientsAm J Med19878334454543477958
   PubMed Web of Science ®Google Scholar
• KantarjianHMKeatingMJEsteyEHTreatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabineJ Clin Oncol19921057727781569449
   PubMed Web of Science ®Google Scholar
• OttmannOGDrukerBJSawyersCLA phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasBlood200210061965197112200353
   PubMed Web of Science ®Google Scholar
• WassmannBKleinSAScheuringUHematologic and cytogenetic remission by STI571(Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantationBone Marrow Transplant200128772172411704799
   PubMed Web of Science ®Google Scholar
• TalpazMSilverRTDrukerBJImatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood20029961928193711877262
   PubMed Web of Science ®Google Scholar
• GuilhotFChastangCMichalletMInterferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study GroupN Engl J Med199733742232299227927
   PubMed Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med200334811994100412637609
   PubMed Web of Science ®Google Scholar
• ShahNPNicollJMNagarBMultiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell20022211712512204532
   PubMed Web of Science ®Google Scholar
• DeiningerMO’BrienSGGuilhotFInternational randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [ASH Annual Meeting Abstract]Blood2009114Abstr 1126
   Web of Science ®Google Scholar
• KantarjianHTalpazMO’brienSSurvival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia – comparison with historic experienceCancer2005103102099210815830345
   PubMed Web of Science ®Google Scholar
• KantarjianHMTalpazMO’BrienSSurvival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemiaBlood200610861835184016709931
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSCortesJImatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataCancer200398122636264214669283
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSGarcia-ManeroGVery long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapyCancer2012118123116312222370904
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSCortesJSurvival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controlsClin Cancer Res2004101 Pt 1687514734453
   PubMed Web of Science ®Google Scholar
• TanakaMFKantarjianHCortesJOhanianMJabbourETreatment options for chronic myeloid leukemiaExpert Opin Pharmacother201213681582822429140
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN)Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia 2010Fort WashingtonNCCN2010 Available from: http://www.24hmb.com/UpLoad/Editor/2010/1/4/2010010471144545.pdfAccessed October 20, 2012
   Google Scholar
• BaccaraniMCortesJPaneFEuropean LeukemiaNetChronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetJ Clin Oncol200927356041605119884523
   PubMed Web of Science ®Google Scholar
• HughesTPKaedaJBranfordSInternational Randomised Study of Interferon versus STI571 (IRIS) Study GroupFrequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaN Engl J Med2003349151423143214534335
   PubMed Web of Science ®Google Scholar
• MarinDMilojkovicDOlavarriaEEuropean LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorBlood2008112124437444418716134
   PubMed Web of Science ®Google Scholar
• AlvaradoYKantarjianHO’BrienSSignificance of suboptimal response to imatinib, as defined by the Europoean LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phaseCancer2009115163709371819517462
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSCortesJEComplete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisCancer20039741033104112569603
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGIRIS InvestigatorsFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
   PubMed Web of Science ®Google Scholar
• HughesTPHochhausABranfordSIRIS InvestigatorsLong-term prognostic significance of early molecular molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood2010116193758376520679528
   PubMed Web of Science ®Google Scholar
• KantarjianHMShanJJonesDSignificance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic responseJ Clin Oncol200927223659366319487383
   PubMed Web of Science ®Google Scholar
• BaccaraniMSaglioGGoldmanJEuropean LeukemiaNetEvolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood200610861809182016709930
   PubMed Web of Science ®Google Scholar
• MarinDIbrahimARLucasCAssessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsJ Clin Oncol201230323223822067393
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHMCortesJEMechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemiaCancer Control200916212213119337198
   PubMed Web of Science ®Google Scholar
• MeloJVChuahCResistance to imatinib mesylate in chronic myeloid leukaemiaCancer Lett2007249212113216949736
   PubMed Web of Science ®Google Scholar
• BranfordSChronic myeloid leukemia: molecular monitoring in clinical practiceHematology Am Soc Hematol Educ Program200737638318024654
   PubMedGoogle Scholar
• BorthakurGKantarjianHMO’BrienSMEfficacy of dasatinib in patients with previously untreated chronic myeloid leukemia in early chronic phase (CML-CP)J Clin Oncol200826Abstr 7013
   Web of Science ®Google Scholar
• JabbourEHochhausACoutrePMinimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)J Clin Oncol200826Abstr 7063
   Web of Science ®Google Scholar
• CortesJO’BrienSJonesDEfficacy of nilotinib (formerly AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase (CML-CP)Blood2008112Abstr 446
   Web of Science ®Google Scholar
• AgrawalMGargRJCortesJQuintás-CardamaAlTyrosine kinase inhibitors: the first decadeCurr Hematol Malig Rep201052708020425399
   PubMed Web of Science ®Google Scholar
• KantarjianHMHochhausASaglioGNilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialLancet Oncol201112984185121856226
   PubMed Web of Science ®Google Scholar
• KantarjianHMShahNPCortesJEDasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood201211951123112922160483
   PubMed Web of Science ®Google Scholar
• DeremerDLUstunCNatarajanKNilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemiaClin Ther200830111956197519108785
   PubMed Web of Science ®Google Scholar
• GolemovicMVerstovsekSGilesFAMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemiaClin Cancer Res200511134941494716000593
   PubMed Web of Science ®Google Scholar
• WeisbergEManleyPWBreitensteinWCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell20057212914115710326
   PubMed Web of Science ®Google Scholar
• WalzCSattlerMNovel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)Crit Rev Oncol Hematol200657214516416213151
   PubMed Web of Science ®Google Scholar
• SattlerMMohiMGPrideYBCritical role for Gab2 in transformation by BCR/ABLCancer Cell20021547949212124177
   PubMed Web of Science ®Google Scholar
• MartinelliGMartelliAMGrafoneTA new Abl kinase inhibitor (AMN107) has in vitro activity on CML Ph+ blast cells resistant to imatinib [ASH Annual Meeting Abstract]Blood2004104Abstr 4687
   Web of Science ®Google Scholar
• KantarjianHGilesFWunderleLNilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med2006354242542255116775235
   PubMed Web of Science ®Google Scholar
• LocktonJASmethurstDMacphersonMPhase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor [ASCO Meeting Abstract]J Clin Oncol20052316S312515860872
   PubMed Web of Science ®Google Scholar
• O’HareTPollockRStoffregenEPInhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLBlood200410482532253915256422
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCGasserMAhmedSAssoulineSScapozzaLAbl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studiesLeukemia20051971267126915858616
   PubMed Web of Science ®Google Scholar
• LombardoLJLeeFYChenPDiscovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysJ Med Chem200447276658666115615512
   PubMed Web of Science ®Google Scholar
• TokarskiJNewittJLeeFYThe crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor [ASH Annual Meeting Abstract]Blood2004104Abstr 553
   Web of Science ®Google Scholar
• ShahNPTranCLeeFYChenPNorrisDSawyersCLOverriding imatinib resistance with a novel ABL kinase inhibitorScience2004305568239940115256671
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantarjianHDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasN Engl J Med2006354242531154116775234
   PubMed Web of Science ®Google Scholar
• BranfordSHughesTNicollJMolecular responses and mutation analysis in imatinib resistant patients with Ph positive leukemia treated with the dual src/abl kinase inhibitor BMS-35482510th Congress of the European Hematology AssociationStockholm2005
   Google Scholar
• GumireddyKBakerSJCosenzaSCA non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistanceProc Natl Acad Sci U S A200510261992199715677719
   PubMed Web of Science ®Google Scholar
• KimuraSNaitoHSegawaHNS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemiaBlood2005106123948395416105974
   PubMed Web of Science ®Google Scholar
• HarringtonEABebbingtonDMooreJVX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivoNat Med200410326226714981513
   PubMed Web of Science ®Google Scholar
• YoungMAShahNPChaoLHStructure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680Cancer Res20066621007101416424036
   PubMed Web of Science ®Google Scholar
• CortesJAlbitarMThomasDEfficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignanciesBlood200310151692169712411300
   PubMed Web of Science ®Google Scholar
• CortesJGarcia-ManeroGO’BrienSPhase I study of a imatinib and tipifarnib (Zarnestra2, R115777) in patients with chronic myeloid leukemia in chronic phase refractory to imatinib [ASH Annual Meeting Abstract]Blood2003102Abstr 3383
   Web of Science ®Google Scholar
• BorthakurGKantarjianHDaleyGPilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyCancer2006106234635216342165
   PubMed Web of Science ®Google Scholar
• MayerhoferMAichbergerKJFlorianSIdentification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cellsFASEB J200519896096215784722
   PubMed Web of Science ®Google Scholar
• LuZJinYQiuLLaiYPanJCelastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutationCancer Lett2010290218219119819619
   PubMed Web of Science ®Google Scholar
• KantarjianHMO’BrienSCortesJResults of decitabine (5-aza-2’deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaCancer200398352252812879469
   PubMed Web of Science ®Google Scholar
• IssaJPGharibyanVCortesJPhase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylateJ Clin Oncol200523173948395615883410
   PubMed Web of Science ®Google Scholar